Enfortumab vedotin Recruiting Phase 3 Trials for Muscle Invasive Bladder Cancer Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Recruiting | Treatment | 3 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT04960709 | Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin |